Marker Therapeutics Inc (MRKR) Stock Price, Quote & News

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 400 6400

Website: markertherapeutics.com

Address:

2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, United States

SinglesOverHomeRun Mar. 31 at 5:07 PM

$MRKR this dog can't even move on a green day. Deport Vera.

0 · Reply

WhereAmIGoing Mar. 31 at 12:46 AM

$MRKR 100 mil dilution coming. No help on the way. Better hope they drop some news first

0 · Reply

SinglesOverHomeRun Mar. 30 at 7:44 PM

$MRKR $XBI Because the President of USA, Mr Netanyahu is going to use the oil from Iran to lubricate these tickers.

1 · Reply

SinglesOverHomeRun Mar. 26 at 11:11 PM

$MRKR you are wrong.

1 · Reply

itsMeRich Mar. 25 at 1:58 PM

$MRKR we smaller shareholders won’t have any impact on the company’s plans, when the institutional holders control the votes……we are at their mercy, and many other promising treatments are already on the market- generating revenue- like IBRX- but I guess I’m just an underwater, disgruntled long.

0 · Reply

tradingviewcyp Mar. 24 at 10:51 PM

$MRKR 100M more shares means, dilution is coming. Wait and buy it below 1$. I hope I am wrong.

0 · Reply

WhereAmIGoing Mar. 24 at 10:37 PM

$MRKR

0 · Reply

Trak2 Mar. 24 at 9:58 PM

$MRKR can somebody double check me and see if institutional ownership has gone up? thank you

0 · Reply

zwark1 Mar. 24 at 9:44 PM

$MRKR Done voted. No on raising the amount of shares.

0 · Reply

blackstratocaster Mar. 24 at 4:01 PM

$MRKR If you have stock, VOTE today. I received my vote link today from Fidelity and just finished. It takes 5 minutes. This issue of increasing the common stock ceiling is up for vote so if you care about that, cast your vote one way or the other. If you have stock and don't vote ...

1 · Reply

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Feb 18, 2026, 8:00 AM EST - 6 weeks ago

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 5, 2026, 7:00 AM EST - 3 months ago

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Nov 14, 2025, 7:00 AM EST - 5 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 7:30 AM EST - 5 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 3, 2025, 9:15 AM EST - 5 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Oct 6, 2025, 7:30 AM EDT - 6 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Aug 28, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 12:34 PM EDT - 7 months ago

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Jul 30, 2025, 8:00 AM EDT - 8 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jun 17, 2025, 8:00 AM EDT - 10 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 11 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 19, 2025, 8:00 AM EDT - 11 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Mar 31, 2025, 8:45 AM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Feb 25, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

May 15, 2024, 4:15 PM EDT - 2 years ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Mar 25, 2024, 5:45 PM EDT - 2 years ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 22, 2024, 12:30 PM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jun 26, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

May 31, 2023, 6:30 AM EDT - 3 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 8, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 1, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Mar 22, 2023, 8:10 AM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

$Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma$

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

SinglesOverHomeRun Mar. 31 at 5:07 PM

$MRKR this dog can't even move on a green day. Deport Vera.

0 · Reply

WhereAmIGoing Mar. 31 at 12:46 AM

$MRKR 100 mil dilution coming. No help on the way. Better hope they drop some news first

0 · Reply

SinglesOverHomeRun Mar. 30 at 7:44 PM

$MRKR $XBI Because the President of USA, Mr Netanyahu is going to use the oil from Iran to lubricate these tickers.

1 · Reply

SinglesOverHomeRun Mar. 26 at 11:11 PM

$MRKR you are wrong.

1 · Reply

itsMeRich Mar. 25 at 1:58 PM

0 · Reply

tradingviewcyp Mar. 24 at 10:51 PM

$MRKR 100M more shares means, dilution is coming. Wait and buy it below 1$. I hope I am wrong.

0 · Reply

WhereAmIGoing Mar. 24 at 10:37 PM

$MRKR

0 · Reply

Trak2 Mar. 24 at 9:58 PM

$MRKR can somebody double check me and see if institutional ownership has gone up? thank you

0 · Reply

zwark1 Mar. 24 at 9:44 PM

$MRKR Done voted. No on raising the amount of shares.

0 · Reply

blackstratocaster Mar. 24 at 4:01 PM

1 · Reply

SinglesOverHomeRun Mar. 23 at 10:46 PM

$MRKR 2.30, 2.20,1.90,1.75,1.60,1.40,1.30, 1.20 >>>1.00

0 · Reply

Trak2 Mar. 20 at 9:26 PM

$MRKR yeah, they are not sharing any plan, for the reason for all those shares, I am hoping they have an agreement with the FDA for one final trial before approval. that would be the only way I would vote yes.

0 · Reply

johnny6nine Mar. 20 at 8:14 PM

$MRKR add a hundred million shares?

1 · Reply

SinglesOverHomeRun Mar. 18 at 9:50 PM

$MRKR the amount is time Apollo was mentioned without providing any new information is freaking irritating. Damn you Apollo Creed! this is really a sh!tty company. no new information whatsoever

0 · Reply

TitusPullo1964 Mar. 12 at 2:41 PM

$MRKR At Boersenplatz Gettex, time today Europe time 3:34 p.m. rate 1.48 dollars

0 · Reply

TitusPullo1964 Mar. 12 at 8:20 AM

$MRKR remember! strong Phase I APOLLO data for its lead T cell therapy MT-601. MT-601 resulted in approximately 66% response in NHL and 78% durable response in Hodgkin's lymphoma. MRKR has further developed MT-601 for dose expansion, secured funding and production support and expects further data in the first half of 2026.

0 · Reply

itsMeRich Mar. 11 at 9:52 PM

$MRKR companies like Immunitybio , appear to be ahead of Marker, with New Killer cell treatment, FDA approval, and over $100M in sales their 1st year. Marker has been dragging this out for way too long…. And it’s apparent, that many are losing interest.

0 · Reply

BCa1 Mar. 11 at 4:10 PM

$MRKR Has anyone read the proposals for the annual meeting? Proposal 3 to increase shares from. 30 to 130 million seems a little excessive. Any thoughts from others would be appreciated. Also they want to restrict the votes required to pass an amendment to the majority of voters present for the proposal. Normal procedure requires majority based on actual number of shares.

2 · Reply

itsMeRich Mar. 9 at 2:36 PM

$MRKR amazed that this has held up pretty well so far….. something must be brewing.

0 · Reply

itsMeRich Mar. 4 at 4:17 PM

$MRKR when can we expect the next catalyst?

0 · Reply

TitusPullo1964 Mar. 4 at 4:11 PM

$MRKR

0 · Reply

SinglesOverHomeRun Mar. 3 at 4:55 PM

$MRKR

0 · Reply

Market Cap	22.01M
Revenue (ttm)	3.55M
Net Income (ttm)	-12.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-342.54%
Debt to Equity Ratio	0.00

Volume	94,200
Avg Vol	189,276
Day's Range	N/A - N/A
Shares Out	16.67M
Stochastic %K	65%
Beta	1.47
Analysts	Strong Sell
Price Target	$7.87